Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.53 |
| ▸ | USP2 | O75604 | 12/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.53 |
| ▸ | TP53 | P04637 | 6/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059385 | 0.76 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2MEN1KMT2AHDAC3 | |
| SCHEMBL1753479 | 0.76 | MCHR1 (0.57) | TSHRCYP3A4 | |
| SCHEMBL1753668 | 0.76 | TSHR (0.50) | TSHRALDH1A1USP2CYP2D6CYP1A2 | |
| SCHEMBL19139673 | 0.73 | TSHR (1.00) | TSHRALDH1A1USP2CYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL30328703 | 0.72 | TSHR (0.96) | TSHRALDH1A1USP2CYP2D6CYP1A2 | |
| SCHEMBL1753724 | 0.71 | TSHR (0.44) | TSHRALDH1A1USP2CYP2D6CYP1A2 | |
| SCHEMBL1001458 | 0.71 | HDAC3 (0.41) | ALDH1A1CYP3A4SMN1; SMN2KMT2AHDAC3 | |
| SCHEMBL1001459 | 0.71 | HDAC3 (0.41) | ALDH1A1CYP3A4SMN1; SMN2KMT2AHDAC3 | |
| SCHEMBL1753499 | 0.69 | MCHR1 (0.55) | CYP3A4 | |
| SCHEMBL14372770 | 0.68 | MCHR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| WO-2008068265-A1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | TSHR 388/4885ALDH1A1 281/4885USP2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.